These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8631015)

  • 1. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
    Kanzawa F; Nishio K; Kubota N; Saijo N
    Cancer Res; 1995 Jul; 55(13):2806-13. PubMed ID: 7796407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
    Masumoto N; Nakano S; Esaki T; Fujishima H; Tatsumoto T; Niho Y
    Int J Cancer; 1995 Jul; 62(1):70-5. PubMed ID: 7601570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
    Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
    Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
    Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
    Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
    Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
    Tsunoda T; Tanimura H; Hotta T; Tani M; Iwahashi M; Ishimoto K; Tanaka H; Matsuda K; Yamaue H
    J Surg Oncol; 2000 Jan; 73(1):6-11. PubMed ID: 10649271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
    Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
    Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
    Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
    Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.